Datasheet
21 Oct 2025
Pipeline
JPG 109 kB
With approved biosimilars already on the market and a robust pipeline of differentiated assets,Polpharma Biologics is well-positioned to shape the future of biosimilars. Strategic collaborationswith industry leaders demonstrate the company’s ability to co-create value and deliver at scale.
Content provided by our supplier
Polpharma Biologics
-
Country/Region:Poland
-
On CPHI since:2021
-
Certificates:3
-
Employees:50 - 99
Company types
Primary activities
Other Content from Polpharma Biologics (4)
-
News Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Polpharma Biologics, announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®* (vedolizumab).
-
News Polpharma Biologics announces approval of Europe’s first and only biosimilar for multiple sclerosis - Tyruko® (natalizumab)
Polpharma Biologics announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe. Tyruko® was developed by Polpharma Biologics and will be commercialized by its collaboration partner Sandoz.
-
News Polpharma Biologics announces FDA approval of Tyruko®
Polpharma Biologics, announced that the FDA is the first regulatory body worldwide to approve the use of Tyruko® (natalizumab-sztn) - a new biosimilar for the treatment of relapsing forms of multiple sclerosis (MS). Approval of Tyruko® by the European Medicines Agency is also expected imminently.
